PPARG and fatty liver disease: Drugs like pioglitazone, a peroxisome proliferator-activated receptor gamma (PPARγ) agonist, and liraglutide, a glucagon like peptide 1 receptor agonist have been shown to reduce liver triglyceride and hepatic steatosis also through reduction of DNL [36,37].